Therefore, we focused on PIP4K2A, a potential target for treating cancer and inflammation, as it catalyzes the production of PI(4.5)P2 and activates the PI3K signaling pathway.[35, 36] Furthermore, RNA‐seq splicing analysis of SLC27A5‐KO HepG2 cells was performed, and the Sashimi plot indicated that the exon skipping occurred at the exon 5 junctions of PIP4K2A. The gene discussed is SLC27A5; the disease is cancer.